acute myeloid leukemia

p53 target new drug! Aprea’s Blood Cancer Combination Therapy Receives FDA Breakthrough Therapy Designation

p53 target new drug! Aprea’s Blood Cancer Combination Therapy Receives FDA Breakthrough Therapy Designation

Aprea Therapeutics is a Boston-based biopharmaceutical company focused on developing and commercializing innovative cancer therapies that reactivate the tumor suppressor protein p53. Recently, the company announced that the U.S. food […]

FDA Recently Approved Three Drugs to Treat Leukemia

FDA Recently Approved Three Drugs to Treat Leukemia

Acute myeloid leukemia (AML) is a rapidly progressing cancer that forms in the bone marrow and results in an increased number of white blood cells in the bloodstream. The National […]

Novel Therapeutics in Acute Myeloid Leukemia

Novel Therapeutics in Acute Myeloid Leukemia

The disparity in clinical outcomes for patients with acute myeloid leukemia (AML) illustrates the heterogeneity of this disease. Overall survival (OS) in AML is impacted by many clinical, cytogenetic, and molecular factors. Although […]